$ATRX News
Last published 3y ago
- 3y agoATRXAdhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesGlobeNewswireData will be instrumental in upcoming Phase 2 clinical trial of MLR-1023, Adhera's novel Type 1 Diabetes drug candidateCompany moving forward with application to transition from OTC to NASDAQ Baton Rouge, LA, Jan. 25,
- 4y agoATRXAdhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ UplistGlobeNewswireBaton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB:ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September 8, 2022, the Company's Board of Directors (the "Board"
- 4y agoATRXAdhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium TransferrinGlobeNewswireBaton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB:ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has entered a Heads of Terms (also known as a Letter of
- 4y agoATRXAdhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQGlobeNewswireBaton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB:ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Trond K. Waerness as Chairman of the Company's B
- 4y agoATRXAdhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory BoardGlobeNewswireBaton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Jean Buteau, PhD., to the Company's Scientifi
- 4y agoATRXAdhera Therapeutics Announces Uplisting to OTCQB Venture MarketplaceGlobeNewswireBaton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB®
- 4y agoATRXAdhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related DisordersGlobeNewswireBaton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new Canadian patent has been issued for MLR-1019 (armesoca
- 5y agoATRXAdhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of DirectorsGlobeNewswireBaton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Zahed Subhan, BS MS PhD MBA LLB, to the Compan
- 5y agoATRXAdhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target IndicationsGlobeNewswireAdhera has an exclusive license agreement with Melior Pharmaceuticals I, pursuant to which Adhera is advancing MLR-1023 (tolimidone) into Phase 2 trials for Type 1 diabetes The agreement has been expanded to allow Adhera to continue completed research
- 5y agoATRXManufacturing Commences on Adhera's MLR-1019 for Phase 2a Clinical Trial Treating Parkinson's DiseaseGlobeNewswireIP Estate Grows with New Korean Patent Issued Baton Rouge, LA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that manufacturing has
- 5y agoATRXAdhera Receives European Patent Covering MLR-1019 and Derivatives for Treating DyskinesiasGlobeNewswireBaton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new European patent has been issued for MLR-1019 (armesoca
- 5y agoATRXAdhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson's Disease and Type 1 Diabetes DrugsGlobeNewswireBaton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an update on corporate strategy and planned clinical develo
- 5y agoATRXAdhera Therapeutics Appoints Dr. Andrew Reaume to Board of DirectorsGlobeNewswireBaton Rouge, LA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Andrew G. Reaume, Ph.D., MBA to the Company's
- 5y agoATRXAdhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug CandidateGlobeNewswireAdhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 – 480,000 patients in U.S.) Laboratory and clinical research support MLR-1023 as the world's first safe, effective beta cell proliferat
- 5y agoATRXAdhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson's Disease Drug CandidateGlobeNewswireAdhera to develop MLR-1019 (armesocarb) as a new class of drug for Parkinson's Disease (PD), representing the only drug to address both movement and non-movement symptoms of PD Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe
- 5y agoATRXAdhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson's DiseaseGlobeNewswireAdhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson's Disease MLR-1019, a Phase 2-ready product, could have substantial benefits over today's Parkinson's drugs, in
- 5y agoATRXAdhera Therapeutics Appoints Trond K. Waerness to Board of DirectorsGlobeNewswireBaton Rouge, LA, April 23, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera Therapeutics" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vacci